HarryD.BearMD

PubMed

• 233 citations
  Current Landscape of Immunotherapy in Breast Cancer: A Review
  Sylvia Adams, Margaret E. Gatti-Mays, Kevin Kalinsky, Larissa A. Korde, Elad Sharon
  JAMA Oncology. 2019-08-01
• 4 citations
  A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim.
  Joseph Mort, Shipra Maheshwari, Nayanika Basu, Patrick Dillon, Kevin Brady
  Case Reports in Oncological Medicine. 2022-01-01
• 42 citations
  Papillary lesions of the breast: To excise or observe?
  Sidrah Khan, Adrian Diaz, Kellie J. Archer, Rebecca R. Lehman, Tiffany Mullins
  The Breast Journal. 2018-05-01

Journal Articles

• Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial  
  Bear, HD, Tang, G, Rastogi, P, Geyer, CE Jr., Liu, Q, Robidoux, A, Baez-Diaz, L, Brufsky, A, Mehta, RS, Fehrenbacher, L, Young, JA, Senecal, FM, Gaur, R, Margolese, RG..., Lancet Oncol, 1/1/2015
• Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma  
  Zoon, C.K., Wan, W., Graham, L., Bear, H.D., Int J Molec Sci, 1/1/2015
• Randomized sham controlled trial of cranial microcurrent stimulation for symptoms of depression, anxiety, pain, fatigue and sleep disturbances in women receiving chemo...  
  Lyon, D. Kelly,D., Walter, J., Bear, H., Thacker, L., Elswick, R.K., SpringerPlus, 1/1/2015
• Commentary on “Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for Stage III breast cancer patients, Shin H-C et al  
  Bear, H.D., Breast Dis Quarterly, 1/1/2014
• Commentary on “Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation,” Boughey et al  
  Bear, H.D., Breast Dis Quarterly, 1/1/2010
• Update: Appropriate Margin Width in Breast Conserving Surgery  
  McKenzie-Johnson, T. and Bear, H.D., Current Breast Cancer Reports, 1/1/2010
• Neoadjuvant Chemotherapy for Operable Breast Cancer: Individualizing Loco-Regional and Systemic Therapy  
  Bear, H.D., Surg Oncol Clinics of North America, 1/1/2010
• Human T cells express CD25 and FoxP3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function  
  Kmieciak, M., Gowda, M., Graham, L., Godder, K., Bear, H.D., Marincola, F.M. and Manjili, M.H., J Transl Med, 1/1/2009
• Adoptive transfer of HER2/neu specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-der...  
  Morales, J.K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H.D., Manjili, M.H., Cancer Immunol Immunotherapy, 1/1/2009
• Measuring circulating tumor cells as a surrogate endpoint for adjuvant therapy of breast cancer: What do they mean and what should we do about them? (Editorial)  
  Bear, H.D., J Clin Oncol, 1/1/2008
• Completion Axillary Lymph Node Dissection for Breast Cancer: Immediate versus Delayed versus None (Editorial)  
  Bear, HD, J Clin Oncol, 1/1/2008
• Statement of the science concerning loco-regional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference  
  Buchholz, T.A., Lehman, C.D., Harris, J.R., Pockaj, B.A., Khouri, N., Hylton, N.F., Miller, M.J., Whelan, T., Pierce, L.J., Esserman, L.J., Newman, L.A., Smith, B.L., ..., J Clin Oncol, 1/1/2008
• Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocols B-18 and B-27  
  Rastogi, P., Anderson, S., Bear, H.D., Geyer, C.E. Jr, Kahlenberg, M.S., Robidoux, A., Margolese, R.G., Hoehn, J.L., Vogel, V.G., Dakhil, S.R., Conley, B.A., King, K...., J Clin Oncol, 1/1/2008
• Reaping the harvest from neoadjuvant therapy for breast cancer: reducing morbidity with sentinel lymph node biopsy (Guest Editorial)  
  Bear, H.D., J Surg Oncol, 1/1/2007
• Imaging multidrug resistance with 4-[(18)F]fluoropaclitaxel  
  Kurdziel, K.A., Kalen, J.D., Hirsch, J.I., Wilson, J.D., Agarwal, R., Barrett, D., Bear, H.D., McCumiskey, J.F., Nucl Med Biol, 1/1/2007
• Neoadjuvant Chemotherapy for Operable Breast Cancer: Lessons from NSABP B-27  
  Habibi, M. and Bear, H.D., Amer J Hem/Onc, 1/1/2006
• Commentary on "Treatment Trends in Early-Stage Invasive Lobular Carcinoma A report from the National Cancer Data Base  
  Bear, H.D., Breast Diseases Quarterly, 1/1/2006
• Sentinel Node Micrometastases and Non-Sentinel Nodes in Breast Cancer: How Much Do We Need to Know? (Editorial)  
  Bear, H.D., J Clin Oncol, 1/1/2006
• A tribute to a surgical oncologist “Been there, done that”  
  Bear, H.D. Walter Lawrence, Jr., J Surg Oncol, 1/1/2005
• Preoperative chemotherapy for operable breast cancer: Lessons learned from a patient and a randomized trial Review  
  Bear, H.D., Amer J Oncol, 1/1/2004
• Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes  
  Chin, C.S., Miller, C.H.T., Graham, L., Parviz, M., Zacur, S., Patel, B., Duong, A., Bear, H.D., Int Immunol, 1/1/2004
• The effect of increasing dose intensity of neoadjuvant chemotherapy for locally advanced breast cancer: Is more and faster better? Review  
  Bear, H.D., Amer J Oncol, 1/1/2003
• Earlier chemotherapy for breast cancer: perhaps too late but still useful (Editorial)  
  Bear, H.D., Ann Surg Oncol, 1/1/2003
• Successful adoptive immunotherapy with vaccine-sensitized T cells despite no effect of vaccination alone in a weakly immunogenic tumor model  
  Parviz, M., Chin, C.S., Graham, L.J., Miller, C., Lee, C., George, K., Bear, H.D., Cancer Immunol Immunother, 1/1/2003
• Partial breast brachytherapy after lumpectomy: Low-dose-rate and high-dose-rate experience  
  Arthur, D.W., Koo, D., Zwicker, R.D., Tong, S., Bear, H.D., Kaplan, B.J., Kavanagh, B.D., Warwicke, L.A., Holdford, D., Amir, C., Schmidt-Ullrich, R.K., Int J Radiation Oncology Biol Phys, 1/1/2003
• Join now to see all

Books/Book Chapters

• Current Surgical Therapy 
  Chapter: Management of Recurrent and Disseminated Breast Cancer 
  Page 650 - 655Bear, H.D., Hackney, M.H., Smith, T.J.Editors: Cameron, J.2004
• Breast Cancer Therapy: Application of Evidence to Patient Management 
  Chapter: Surgical considerations in breast cancer patients treated with preoperative chemotherapy. Chapter 6 
  Page 67 - 83Bear, H.D.Editors: Nabholtz, J-M, Tonkin, K, Reese, DM, Aapro, MS, Buzdar, AU.Lippincott Williams & Wilkins, Philadelphia, PAEdition 2nd,2003
• Surgical Research 
  Chapter: Approaches to Adoptive Immunotherapy, Chapter 35 
  Page 415 - 434Bear, H.D., Chin, C.S.Editors: W. Souba and D. Wilmore.Academic Press, San Diego, CA2001
• Breast Cancer Therapy: Application of Evidence to Patient Management 
  Chapter: Surgical considerations in breast cancer patients treated with preoperative chemotherapy. Chapter 22 
  Page 253 - 273Bear, H.D.Editors: Nabholtz,J-M, Tonkin,K, Aapro,MS, Buzdar, AU.Martin Dunitz, London2000
• Cancer Surgery for the General Surgeon 
  Chapter: Melanoma, Chapter 11 
  Page 137 - 154Winchester, D.P., Daly, J.M., Jones, R.S., Murphy,G.P.IIIEditors: Lippincott Williams & Wilkins.Philadelphia, PA1999
• Manual of Clinical Laboratory Immunology 
  Chapter: Human tumor-associated antigens recognized by T lymphocytes. 
  Page 1035 - 1040Bear, H.D.Editors: N.R. Rose, E.C. de Macario, J.D. Folds, H.C. Lane, R.M. Nakamura.ASM Press, Washington, DCEdition 5th,1997
• Immunotherapy of Cancer with Sensitized T Lymphocytes 
  Chapter: Adoptive immunotherapy with pharmacologically activated T lymphocytes. 
  Page 35 - 51Bear, H.D. and Tuttle, T.M.Editors: A.E. Chang and S. Shu.R.G. Landes Publishing, Austin, TX1994
• Cellular Immunity and the Immunotherapy of Cancer 
  Chapter: A P815-specific cytotoxic T lymphocyte clone dependent upon tumor cell stimulation and exogenous interleukin 2 for proliferation. 
  Page 303 - 306Hoover,S.K., Inge, T.H., Bear, H.D.Editors: M.T. Lotze and O.J. Finn.1990
• Progress in Clinical and Biological Research, v. 292, Biological and Synthetic Membranes 
  Chapter: Cytosolic-mitochondrial interactions (mitochondrial control of glycolysis). 
  Page 497 - 506Brandt,R.B., Laux,J.E., Spainhour,S.E., Bear, H.D., Kline,E.S.Editors: D.A. Butterfield.Alan R. Liss, Inc., New York, NY1989
• Join now to see all

Abstracts/Posters

• Augmentation of adoptive cellular immunotherapy for breast cancer with decitabine.
  Terracina, KP, Graham, LJ, Payne, K, Manjili, MH, Bear, HD., Society of Surgical Oncology 68th Annual Cancer Symposium, 1/1/2015
• The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40.
  Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, Jr., Qing Liu, André Robidoux, James N. Atkins, Luis Baez-Diaz, Adam M. Brufsky, Rita S. Mehta, Louis Fehren..., SABCS, 1/1/2014
• A phase ii study of [(18)F]-3'DEOXY-3'-fluorothymidine positron emission tomography (FLT-PET) in the assessment of early response in locally advanced breast cancer (LA...
  Bear, H.D., ASCO, 1/1/2014
• Cancer immunotherapy: treatment of established breast cancer or prevention of tumor relapse and metastasis?
  Payne, KK, Graham, L, Bear, HD, Manjili, MH, J Immunol, 1/1/2014
• Immunotherapy of cancer: re-programming tumor-immune cross-talk.
  Payne, KK, Hall, CE, Toor, AA, Bear, HD, Wang, X-Y, Manjili, MH, J.Immunother, 1/1/2012
• Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.
  Robidoux A, Tang G, Rastogi P, Geyer Jr CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Kuebler JP, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Band..., ASCO Proceedings, 1/1/2012
• Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients.
  Maria Libera Ascierto, Michael O Idowu, Yingdong Zhao, Davide Bedognetti, Paolo Antonio Ascierto, Harry Douglas Bear, Ena Wang, Franco Marincola, Andrea De Maria, Maso..., J Clin Oncol; ASCO Proceedings, 1/1/2012
• Human dosimetry and preliminarily tumor distribution of F-18 fluoropaclitaxel (FPAC ) in normal volunteers and breast cancer patients using PET/CT.
  McCumiskey,J., Bear, H., Hirsch, J., Kalen, J., Sykes, K., Kurdziel, K., Society for Nuclear Medicine, 1/8/2011
• Multi-spectral fluorescence imaging of adoptive immune cell therapy using a cell membrane probe.
  Youniss,F., Sundaresan,G., Graham,L., Berry,C., Bear,H., Zweit, J., Society for Nuclear Medicine, 1/1/2011
• L'HeureuxACRIN 6688 Phase II study of fluorine-18 3'-deoxy-3' fluorothymidine (FLT) in invasive breast cancer.
  P. R. Jolles, L. Kostakoglu, H. D. Bear, M. O. Idowu, K. A. Kurdziel, L. Shankar, D. A. Mankoff, F. Duan, D., J Clin Oncol; ASCO, 1/1/2011
• The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP Protocol B-40.
  Bear, H.D., Tang, G., Rastogi, P., Geyer, C.E., Robidoux, A., Atkins, J.N., Baez-Diaz, L., Brufsky, A., Mehta, R.S., Fehrenbacher, L., Pajon, E.R., Colman, L.K., Gaur,..., J Clin Oncol; ASCO, 1/1/2011
• A genomic predictor developed from breast cancer cell lines predicts both disease-free survival and overall survival in breast cancer patients treated with doxorubicin...
  Shen, K, Tang, G, Kim, C, Pogue-Geile, K, Anderson, SJ, Costantino, JP, Bear, HD, Song, N, Tian, C, Gabrin, MJ, Zhang, Y, Geyer, Jr. CE, Wolmark, N., Cancer Res, 1/1/2011
• The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40.
  Bear, HD, G Tang, P Rastogi, CE Geyer Jr, A Robidoux, JN Atkins, L Baez-Diaz, AM Brufsky, RS Mehta, L Fehrenbacher, ER Pajon, FM Senecal, R Gaur, RG Margolese, PT Adam..., Cancer Res, 1/1/2011
• L’Heureux DZ. ACRIN 6688 Phase II Study of Fluorine-18 3’-Deoxy-3’Fluorothymidine (FLT) in Invasive Breast Cancer.
  Jolles PJ, Kostakoglu L, Bear HD, Idowu MO, Kurdziel K, Shankar, Cancer Res, 1/1/2011
• Immunological markers associated with favorable prognosis in breast cancer patients: Role of the innate immune system.
  Ascierto, ML, Kmieciak, M, Idowu, MO, Bedognetti, A, DMaria, Bear, HD, Wang, E, Marincola,F, Manjili, M., ASCO Breast, 1/1/2011
• Surgical resection of primary tumor in metastatic breast cancer reduces overall tumor burden and improves survival.
  Rashid, O.M., Nagahashi, M., Ramachandran, S., Milstein, S., Spiegel, S., Bear, H.D., Takabe, K., ACS Surgical Forum, 1/1/2011
• Signatures of immune function genes associated with recurrence-free survival in breast cancer patients.
  Ascierto, M.-L., Kmieciak, M., Idowu, M.O., Grimes, M., Dumur, C., Wang, E., Manrincola, F.M., Bear, H.D., Manjili, M.H., ISBTC 25th Annual Meeting, 1/2/2010
• Sequential common gamma chain cytokines facilitate differentiation of tumor-reactive T cells that are refractory to MDSC and can induce rejection of breast cancer upon...
  Kmieciak, M., Basu, D., Bear, H.D., Manjili, M.H., MDSC Symposium, 1/2/2010
• Predictors of loco-regional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): Results from combined analysis of NSABP B-18 and NSABP B-27.
  E. P. Mamounas, S. J. Anderson, H. D. Bear, T. B. Julian, C. E. Geyer, B. Fisher, D. L. Wickerham, N. Wolmark, ASCO Breast Symposium, 1/1/2010
• A novel model of myeloid-derived suppression of the anti-tumor response: Overexpression of ADAM10 promotes myeloid-derived suppressor cell expansion in a tumor-free en...
  Gibb,DR, Saleem,SJ, Kang,D-J, Kmieciak, M, Bear, HD, Manjili, MH and Conrad, DH., Molecular and Cellular Biology of Immune Escape in Cancer: Keystone Symposium, Keystone, CO, 1/1/2010
• Predictive Factors for Positive Non-sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32.
  Julian, T.B., Anderson, S.J., Golesorkhi, N., Fourchotte, V., Zheng, P, Mamounas, E.P., Brown, A.M., Boudros, E., Bear, H., Costantino, J.P., Wolmark, N., 32nd Annual San Antonio Breast Cancer Symposium, 1/1/2009
• Radiofrequency ablation of breast tumors along with the intralesional administration of IL-7 and IL-15 induce anti-tumor immune responses and inhibit tumor development...
  Habibi, M., Manjili, M., Bear, H.D., Keeler, J.M., Kmieciak, M, Ann of Surg Oncol, 1/1/2008
• Effects of surgical excision of primary breast tumor on survival of patients with Stage IV disease.
  Leung, A., Nguyen, K. Thacker, L., Bear, H.D., Vu, H., Ann of Surg Oncol, 1/1/2008
• PNI-based stress management in early breast cancer.
  McCain, N. L., Walter, J.M., Bear, H.D., Elswick, R.K., Gray, D.P., Robins, J.W., Smith, T., Tuck, I., NCI Translational Science Meeting, Washington, DC, 1/1/2008
• Is completion axillary dissection always required after a positive sentinel node biopsy? NSABP B-32.
  Julian TB, Anderson SJ, Fourchotte V, Brown AM, Boudros E, Mamounas EP, Bear H, Costantino JP and Wolmark N, Breast Cancer Res Treatment, 1/1/2007
• Join now to see all

Lectures

• Molecular Profiling: Hormone Therapy vs. Chemotherapy 
  San Juan, Puerto Rico - 1/3/2015
• Timing of Sentinel Node Biopsy 
  San Juan, Puerto Rico - 1/3/2015
• Update on NSABP/NRG Breast Cancer Clinical Trials 
  San Juan, Puerto Rico - 1/2/2015
• How to Use Neoadjuvant Systemic Therapy to Improve Surgical Outcomes for Breast Cancer 
  Vancouver, British Columbia, Canada - 1/20/2014
• Genomic Classifiers Across the Breast Cancer Spectrum 
  Nashua, NH - 1/3/2014
• Women's Health 2013: The 21st Annual Congress 
  Academy of Women's Health, Washington, Dist Of Col - 3/22/2013
• Surgery and Primary Systemic Treatment of Breast Cancer: Key Concepts and New Approaches 
  South Hill, VA - 1/28/2013
• Breast Cancer - What's New 
  Washington, DC - 1/23/2013
• Genomic Classifiers across the Breast Cancer Spectrum: Applications in DCIS, Node Positive Disease, and Locally Advanced Breast Cancer 
  Singapore - 1/13/2013
• Sentinel Lymph Node Biopsy in Patients with Node-Positive Cancer Treated with Neoadjuvant Therapy: Is It Safe? – Con 
  San Francisco, CA - 1/8/2013
• OncotypeDx Utility in Neo-Adjuvant Disease: Insights into the Importance of Recurrence Score in Managing ER+ Locally Advanced Breast Cancer 
  Cancun, Mexico - 1/4/2013
• Local and Regional Management of Breast Cancer Treated with Neoadjuvant Chemotherapy 
  Milwaukee, WI - 1/2/2013
• 7th Annual Breast Cancer Symposium 
  Northwest AHEC, Grantsboro, North Carolina - 9/7/2012
• Neoadjuvant Therapy for Breast Cancer: Surgical Issues, Molecular Genetics and Opportunities for Discovery 
  Carolinas Medical Center, Charlotte, NC - 1/10/2012
• Pre-operative Chemotherapy and Implications for Surgery 
  Greensboro, NC - 1/7/2012
• Locoregional Management after Neoadjuvant Chemotherapy 
  San Francisco, CA - 1/25/2011
• Molecular Profiling in Breast Cancer 
  San Juan, Puerto Rico - 1/25/2011
• Neoadjuvant therapy in Breast Cancer 
  San Juan, Puerto Rico - 1/25/2011
• Neoadjuvant Systemic Therapy for Breast Cancer: Surgical Planning and Execution 
  Hot Springs, VA - 1/24/2011
• Sentinel Lymph Node Biopsy and the Declining Role of Axillary Node Dissection for Breast Cancer 
  Hot Springs, VA - 1/24/2011
• Decision-Making Tools In Early-Stage Breast Cancer 
  San Juan, Puerto Rico - 1/22/2011
• Neoadjuvant Therapy for Breast Cancer: Molecular Genetics, Surgical Issues and Opportunities for Discovery 
  Greenville, SC - 1/3/2011
• Neoadjuvant Therapy for Breast Cancer: Surgical Issues and Opportunities for Discovery 
  Brigham & Women's Hospital, Boston, MA - 1/2/2011
• Clinical Role of Molecular Profiling of Breast Cancers 
  Charleston, SC - 1/30/2010
• Surgical Management of the Breast and Axilla in Patients Receiving Neoadjuvant Chemotherapy 
  Charleston, SC - 1/30/2010
• Join now to see all

Other

• Role of Taxanes in Primary Systemic Therapy of Breast Cancer. in "New Perspectives of Targeted Therapy of Breast Cancer: The Role of Taxanes in Adjuvant Breast Cancer ... 
  Bear, H.D., NMCR monograph
  1/1/2006
• Management of early stage breast cancer: Palpable symptomatic mass. (videorecording) 
  Bear, H.D., Simonson, C., Smith, T.J., Swisher, K., Williams, R.B., Lawrence, W. Jr., Virginia Hospital Television Network, Office of Medical Education,
  Virginia Commonwealth University, Richmond,VA - 1/1/1991
• Doctoral Thesis: Anti-ldiotype Antibody to Alloantibody of a Single Specificity 
  Bear, H.D.
  1/1/1978